[천지일보=홍보영 기자] GC Well-Being introduces the first Korean-injected joint cavity injection that has undergone clinical trials in Korea. GC Wellbeing announced on the 13th that it has recently launched Conrod, an intra-articular injection for patients with degenerative arthritis.
Unlike existing products that have been clinically tested for Europeans, this product has been tested for safety and efficacy in Koreans.
Conrod is an intra-articular injection containing polynucleotide sodium (PN) extracted from the DNA of salmonid fish.
This product is effective in improving knee pain by reducing physical friction in the joints. It has obtained the European Community Mark (CE) and has been certified for suitability for entry into the European market.
BR Pharm, the manufacturer of the product, improved the quality of the product through domestic eco-friendly sea trout farming and history management, and secured safety by extracting high-purity PN using a patented manufacturing method. In addition, it produces raw materials and finished products on its own in a GMP-certified domestic production facility.
An official from GC Wellbeing said, “The domestic joint cavity treatment market is growing rapidly due to the increase in the number of degenerative arthritis patients.
Copyright © Cheonji Ilbo – New Era Hope Press Prohibition of unauthorized reproduction and redistribution
